Progress made by company is slow

By: |
New Delhi | July 02, 2018 4:29 AM

Even as patanjali is not gaining incremental market share anymore, CLGT is not wresting back any of the lost share either, unlike what a Dabur is reporting in Honey and Chyawanprash.

Patanjali is not gaining incremental market share anymore

Even as patanjali is not gaining incremental market share anymore, CLGT is not wresting back any of the lost share either, unlike what a Dabur is reporting in Honey and Chyawanprash. Underlying category volume growth is inching up but at a slow pace. CLGT, on its part, is stepping up A&P investments behind Swarna Vedshakti, the company’s flagship challenger brand in the naturals segment. We lower our volume growth assumptions a tad and increase A&P estimates, driving a 4.2-4.4% cut in FY2019-21e EPS forecasts. TP retained on DCF rollover to June 2019e. Add.

Underlying category growth — gradual improvement even as hopes of acceleration are intact: Our checks and discussions with CLGT suggest modest improvement in underlying category growth rates. The company remains hopeful of a rural-recovery-led acceleration driven by MSP increases, a third consecutive normal monsoon and pre-election spending surge. To be sure, this is not supported yet by any meaningful demand inflection signs. Premiumisation trends remain weak with the multi-benefit Total franchise, the sensitivity range and the whitening portfolio continuing to be drags. The core CDC franchise is stable while the freshness (Maxfresh) range remains one of the bright spots.

Stepping up A&P investments; confident of GM sustenance: Likely price increases should take care of input cost inflation trends, in our view. We do gather that CLGT has stepped up A&P investments behind Swarna Vedshakti and that A&P could remain elevated for the next few quarters.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Zydus Wellness: Maintain ‘buy’; TP unchanged at Rs 2,500
2Dabur India: Downgrade to ‘hold’ with new TP of Rs 580
3Maharashtra mandis report 20% loss due to lockdown